CDK9 and prostate carcinoma: NEAT1 serves as a bridge to facilitate the binding between the major regulatory transcriptional kinase cyclin-dependent kinase 9 (CDK9) and its regulatory subunit cyclin L1 in prostate cancer cells [32].